Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Inozyme Pharma, Inc. Income Statement Banner

Inozyme Pharma, Inc. Income Statement

INZY Stock Analysis

Page title

Section title

Breakdown
2018
2019
2020
2021
2022
2023
Total Revenue
0.0000.0000.0000.0000.0000.000
Cost of Revenue
26.000K83.000K217.000K1.052M1.177M1.294M
Gross Profit
-26.000k-83.000k-217.000k-1.052m-1.177m-1.294m
Operating Expense
11.593M20.806M57.041M56.646M68.675M74.351M
Operating Income
-11.593m-20.806m-57.041m-56.646m-68.675m-75.645m
Other Income Expense
4.345M-24.000k247.000K-189.000k-319.000k0.000
Total Other Income Expense
4.345M1.082M617.000K22.000K1.614M4.476M
Pretax Income
-6.964m-19.724m-56.424m-56.624m-67.061m-71.169m
Tax Provision
4.629M-1.106m-587.000k-211.000k-1.614m0.000
Net Income
-6.964m-18.618m-55.837m-56.413m-65.447m-71.169m
Basic EPS
-0.460-1.230-2.390-2.390-1.730-1.370
Diluted EPS
-0.460-1.230-2.390-2.390-1.730-1.370
Basic Average Shares
15.137M15.159M23.385M23.558M37.763M51.839M
Diluted Average Shares
15.137M15.159M23.385M23.558M37.763M51.839M
Total Expenses
11.593M20.806M57.041M56.646M68.675M75.645M
Interest Income
284.000K1.106M370.000K211.000K1.933M7.837M
Interest Expense
0.0000.0000.0000.000-1.614m3.333M
EBITDA
-11.567m-20.723m-57.041m-55.972m-68.675m-74.351m
Depreciation & Amortization
26.000K83.000K217.000K1.052M1.177M1.294M